HDAC9 and cancer: VPA, mocetinostat, and tubastatin A, which are inhibitors of Class I and II HDASs, have been reported with strong anti-cancer activity in a variety of human cancers.10, 11, 12 However, it is unclear which HDAC is the most important target for treating and understanding various cancers.